Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin

Yukinari Kato, Satoshi Ogasawara, Hiroharu Oki, Ryusuke Honma, Michiaki Takagi, Yuki Fujii, Takuro Nakamura, Noriko Saidoh, Hazuki Kanno, Mitsuo Umetsu, Satoshi Kamata, Hiroshi Kubo, Mitsuhiro Yamada, Yoshihiko Sawa, Kei Ichi Morita, Hiroyuki Harada, Hiroyoshi Suzuki, Mika Kato Kaneko

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Podoplanin (PDPN) is a type-I transmembrane sialoglycoprotein, which possesses a platelet aggregation-stimulating (PLAG) domain in its N-terminus. Among the three PLAG domains, O-glycan on Thr52 of PLAG3 is critical for the binding with C-type lectin-like receptor-2 (CLEC-2) and is essential for platelet-aggregating activity of PDPN. Although many anti-PDPN monoclonal antibodies (mAbs) have been established, almost all mAbs bind to PLAG domains. We recently established CasMab technology to produce mAbs against membranous proteins. Using CasMab technology, we produced a novel anti-PDPN mAb, LpMab-17, which binds to non-PLAG domains. LpMab-17 clearly detected endogenous PDPN of cancer cells and normal cells in Western-blot, flow cytometry, and immunohistochemistry. LpMab-17 recognized glycan-deficient PDPN in flow cytometry, indicating that the interaction between LpMab-17 and PDPN is independent of its glycosylation. The minimum epitope of LpMab-17 was identified as Gly77-Asp82 of PDPN using enzyme-linked immunosorbent assay. Of interest, LpMab-17 did not bind to monkey PDPN, whereas the homology is 94% between human PDPN and monkey PDPN, indicating that the epitope of LpMab-17 is unique compared with the other anti-PDPN mAbs. The combination of different epitope-possessing mAbs could be advantageous for the PDPN-targeting diagnosis or therapy.

Original languageEnglish
Pages (from-to)109-116
Number of pages8
JournalMonoclonal Antibodies in Immunodiagnosis and Immunotherapy
Volume35
Issue number2
DOIs
Publication statusPublished - Apr 1 2016
Externally publishedYes

Fingerprint

Haplorhini
Monoclonal Antibodies
Technology
Platelet Aggregation
Epitopes
Polysaccharides
Flow Cytometry
Sialoglycoproteins
C-Type Lectins
Glycosylation
Blood Platelets
Western Blotting
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Neoplasms
Proteins
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin. / Kato, Yukinari; Ogasawara, Satoshi; Oki, Hiroharu; Honma, Ryusuke; Takagi, Michiaki; Fujii, Yuki; Nakamura, Takuro; Saidoh, Noriko; Kanno, Hazuki; Umetsu, Mitsuo; Kamata, Satoshi; Kubo, Hiroshi; Yamada, Mitsuhiro; Sawa, Yoshihiko; Morita, Kei Ichi; Harada, Hiroyuki; Suzuki, Hiroyoshi; Kaneko, Mika Kato.

In: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Vol. 35, No. 2, 01.04.2016, p. 109-116.

Research output: Contribution to journalArticle

Kato, Y, Ogasawara, S, Oki, H, Honma, R, Takagi, M, Fujii, Y, Nakamura, T, Saidoh, N, Kanno, H, Umetsu, M, Kamata, S, Kubo, H, Yamada, M, Sawa, Y, Morita, KI, Harada, H, Suzuki, H & Kaneko, MK 2016, 'Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin', Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, vol. 35, no. 2, pp. 109-116. https://doi.org/10.1089/mab.2015.0077
Kato, Yukinari ; Ogasawara, Satoshi ; Oki, Hiroharu ; Honma, Ryusuke ; Takagi, Michiaki ; Fujii, Yuki ; Nakamura, Takuro ; Saidoh, Noriko ; Kanno, Hazuki ; Umetsu, Mitsuo ; Kamata, Satoshi ; Kubo, Hiroshi ; Yamada, Mitsuhiro ; Sawa, Yoshihiko ; Morita, Kei Ichi ; Harada, Hiroyuki ; Suzuki, Hiroyoshi ; Kaneko, Mika Kato. / Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin. In: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 2016 ; Vol. 35, No. 2. pp. 109-116.
@article{eb5240425894480480fa678da3f441d8,
title = "Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin",
abstract = "Podoplanin (PDPN) is a type-I transmembrane sialoglycoprotein, which possesses a platelet aggregation-stimulating (PLAG) domain in its N-terminus. Among the three PLAG domains, O-glycan on Thr52 of PLAG3 is critical for the binding with C-type lectin-like receptor-2 (CLEC-2) and is essential for platelet-aggregating activity of PDPN. Although many anti-PDPN monoclonal antibodies (mAbs) have been established, almost all mAbs bind to PLAG domains. We recently established CasMab technology to produce mAbs against membranous proteins. Using CasMab technology, we produced a novel anti-PDPN mAb, LpMab-17, which binds to non-PLAG domains. LpMab-17 clearly detected endogenous PDPN of cancer cells and normal cells in Western-blot, flow cytometry, and immunohistochemistry. LpMab-17 recognized glycan-deficient PDPN in flow cytometry, indicating that the interaction between LpMab-17 and PDPN is independent of its glycosylation. The minimum epitope of LpMab-17 was identified as Gly77-Asp82 of PDPN using enzyme-linked immunosorbent assay. Of interest, LpMab-17 did not bind to monkey PDPN, whereas the homology is 94{\%} between human PDPN and monkey PDPN, indicating that the epitope of LpMab-17 is unique compared with the other anti-PDPN mAbs. The combination of different epitope-possessing mAbs could be advantageous for the PDPN-targeting diagnosis or therapy.",
author = "Yukinari Kato and Satoshi Ogasawara and Hiroharu Oki and Ryusuke Honma and Michiaki Takagi and Yuki Fujii and Takuro Nakamura and Noriko Saidoh and Hazuki Kanno and Mitsuo Umetsu and Satoshi Kamata and Hiroshi Kubo and Mitsuhiro Yamada and Yoshihiko Sawa and Morita, {Kei Ichi} and Hiroyuki Harada and Hiroyoshi Suzuki and Kaneko, {Mika Kato}",
year = "2016",
month = "4",
day = "1",
doi = "10.1089/mab.2015.0077",
language = "English",
volume = "35",
pages = "109--116",
journal = "Monoclonal Antibodies in Immunodiagnosis and Immunotherapy",
issn = "2167-9436",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin

AU - Kato, Yukinari

AU - Ogasawara, Satoshi

AU - Oki, Hiroharu

AU - Honma, Ryusuke

AU - Takagi, Michiaki

AU - Fujii, Yuki

AU - Nakamura, Takuro

AU - Saidoh, Noriko

AU - Kanno, Hazuki

AU - Umetsu, Mitsuo

AU - Kamata, Satoshi

AU - Kubo, Hiroshi

AU - Yamada, Mitsuhiro

AU - Sawa, Yoshihiko

AU - Morita, Kei Ichi

AU - Harada, Hiroyuki

AU - Suzuki, Hiroyoshi

AU - Kaneko, Mika Kato

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Podoplanin (PDPN) is a type-I transmembrane sialoglycoprotein, which possesses a platelet aggregation-stimulating (PLAG) domain in its N-terminus. Among the three PLAG domains, O-glycan on Thr52 of PLAG3 is critical for the binding with C-type lectin-like receptor-2 (CLEC-2) and is essential for platelet-aggregating activity of PDPN. Although many anti-PDPN monoclonal antibodies (mAbs) have been established, almost all mAbs bind to PLAG domains. We recently established CasMab technology to produce mAbs against membranous proteins. Using CasMab technology, we produced a novel anti-PDPN mAb, LpMab-17, which binds to non-PLAG domains. LpMab-17 clearly detected endogenous PDPN of cancer cells and normal cells in Western-blot, flow cytometry, and immunohistochemistry. LpMab-17 recognized glycan-deficient PDPN in flow cytometry, indicating that the interaction between LpMab-17 and PDPN is independent of its glycosylation. The minimum epitope of LpMab-17 was identified as Gly77-Asp82 of PDPN using enzyme-linked immunosorbent assay. Of interest, LpMab-17 did not bind to monkey PDPN, whereas the homology is 94% between human PDPN and monkey PDPN, indicating that the epitope of LpMab-17 is unique compared with the other anti-PDPN mAbs. The combination of different epitope-possessing mAbs could be advantageous for the PDPN-targeting diagnosis or therapy.

AB - Podoplanin (PDPN) is a type-I transmembrane sialoglycoprotein, which possesses a platelet aggregation-stimulating (PLAG) domain in its N-terminus. Among the three PLAG domains, O-glycan on Thr52 of PLAG3 is critical for the binding with C-type lectin-like receptor-2 (CLEC-2) and is essential for platelet-aggregating activity of PDPN. Although many anti-PDPN monoclonal antibodies (mAbs) have been established, almost all mAbs bind to PLAG domains. We recently established CasMab technology to produce mAbs against membranous proteins. Using CasMab technology, we produced a novel anti-PDPN mAb, LpMab-17, which binds to non-PLAG domains. LpMab-17 clearly detected endogenous PDPN of cancer cells and normal cells in Western-blot, flow cytometry, and immunohistochemistry. LpMab-17 recognized glycan-deficient PDPN in flow cytometry, indicating that the interaction between LpMab-17 and PDPN is independent of its glycosylation. The minimum epitope of LpMab-17 was identified as Gly77-Asp82 of PDPN using enzyme-linked immunosorbent assay. Of interest, LpMab-17 did not bind to monkey PDPN, whereas the homology is 94% between human PDPN and monkey PDPN, indicating that the epitope of LpMab-17 is unique compared with the other anti-PDPN mAbs. The combination of different epitope-possessing mAbs could be advantageous for the PDPN-targeting diagnosis or therapy.

UR - http://www.scopus.com/inward/record.url?scp=84965176276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965176276&partnerID=8YFLogxK

U2 - 10.1089/mab.2015.0077

DO - 10.1089/mab.2015.0077

M3 - Article

VL - 35

SP - 109

EP - 116

JO - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

JF - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

SN - 2167-9436

IS - 2

ER -